Peptidylglycine α-amidating monooxygenase and adrenomedullin measurement in patients with hepatic cirrhosis

Jens P Goetze*, Andrei Voiosu, Signe Wiese, Janin Schulte, Paul Kaufmann, Andreas Bergmann, Emil D Bartels, Søren Møller

*Corresponding author for this work

Abstract

Background: Peptidylglycine α-amidating mono-oxygenase (PAM) is an enzyme involved in the maturation of regulatory peptides. Here we examined PAM activity and adrenomedullin (bio-ADM) concentrations in patients with hepatic cirrhosis and determined net changes across the liver, kidneys and leg. Materials & methods: A total of 48 patients with hepatic cirrhosis and 16 control subjects were included. All patients and controls underwent an invasive procedure with blood collected across organs. Results: PAM activity was increased in cirrhotic patients but without a net change across the liver, leg or kidney. In contrast, bio-ADM concentrations were associated with severity of disease and found to be higher in venous blood from the liver. Conclusion: Increased PAM activity in patients with hepatic cirrhosis may reflect other organs involved in cirrhotic disease.

Original languageEnglish
JournalBiomarkers in Medicine
Volume17
Issue number13
Pages (from-to)577-583
Number of pages7
ISSN2050-7771
DOIs
Publication statusPublished - Oct 2023

Keywords

  • Adrenomedullin
  • Humans
  • Liver Cirrhosis
  • Mixed Function Oxygenases
  • Multienzyme Complexes

Fingerprint

Dive into the research topics of 'Peptidylglycine α-amidating monooxygenase and adrenomedullin measurement in patients with hepatic cirrhosis'. Together they form a unique fingerprint.

Cite this